Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Pulmonary Hypertension, April 2024 Free Subscription Abstracts Retrieve all available abstracts of the following 102 articles: HTML format

Single Articles

1. INTERNATIONAL BR
   Retracted: Curcumin Improves Pulmonary Hypertension Rats by Regulating Mitochondrial Function.
   Biomed Res Int. 2024;2024:9769323.
   PubMed    
   Abstract available
   
   

2. MENG X, Du L, Xu S, Zhou L, et al
   Periodontitis exacerbates pulmonary hypertension by promoting IFNgamma(+) T cell infiltration in mice.
   Int J Oral Sci. 2024;16:27.
   PubMed    
   Abstract available
   
   

3. GHOFRANI HA, Simonneau G, D'Armini AM, Fedullo P, et al
   Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
   Lancet Respir Med. 2024;12:e21-e30.
   PubMed    
   Abstract available
   
   

4. MA RZ, Jin CL, Yang S, Han PP, et al
   Evaluating the efficacy of balloon pulmonary angioplasty using quantitative analysis of SPECT pulmonary ventilation/perfusion scintigraphy in patients with chronic thromboembolic pulmonary hypertension.
   Quant Imaging Med Surg. 2024;14:2590-2602.
   PubMed    
   Abstract available
   
   

5. NORTON CE
   Role of Sensory Nerves in Pulmonary Fibrosis.
   Int J Mol Sci. 2024;25:3538.
   PubMed    
   Abstract available
   
   

6. SYKORA M, Szeiffova Bacova B, Andelova K, Egan Benova T, et al
   Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension.
   Int J Mol Sci. 2024;25:3275.
   PubMed    
   Abstract available
   
   

7. VAIDYA A, Vaidy A, Al-Otaibi M, Zlotshewer B, et al
   Pelvic Vein Obstruction in Chronic Thromboembolic Pulmonary Hypertension: A Novel Association.
   J Clin Med. 2024;13:1553.
   PubMed    
   Abstract available
   
   

8. LECKA-AMBROZIAK A, Kot K
   Pulmonary Hypertension and Hypothyroidism-Still an Important Clinical Coincidence in Paediatric Population, an Endocrinologist's Point of View.
   Life (Basel). 2024;14:302.
   PubMed    
   Abstract available
   
   

9. IVANAUSKIENE T, Cesna S, Grigoniene E, Gumbiene L, et al
   Balloon Pulmonary Angioplasty for Inoperable Chronic Thromboembolic Pulmonary Hypertension: Insights from a Pilot Low-Volume Centre Study and a Comparative Analysis with Other Centres.
   Medicina (Kaunas). 2024;60:461.
   PubMed    
   Abstract available
   
   

10. MOISII P, Jari I, Naum AG, Butcovan D, et al
    Takayasu's Arteritis: A Special Case Report and Review of the Literature.
    Medicina (Kaunas). 2024;60:456.
    PubMed    
    Abstract available
    
    

11. NAGAI Y, Murayama M, Kaga S, Shima H, et al
    Echocardiographic estimation of right ventricular diastolic stiffness based on pulmonary regurgitant velocity waveform analysis in precapillary pulmonary hypertension.
    Int J Cardiovasc Imaging. 2024 Mar 27. doi: 10.1007/s10554-024-03083.
    PubMed    
    Abstract available
    
    

12. GARCIA-LUNAR I, Jorge I, Saiz J, Solanes N, et al
    Metabolic changes contribute to maladaptive right ventricular hypertrophy in pulmonary hypertension beyond pressure overload: an integrative imaging and omics investigation.
    Basic Res Cardiol. 2024 Mar 27. doi: 10.1007/s00395-024-01041.
    PubMed    
    Abstract available
    
    

13. SCHANZ O, Criner GJ, Rali P, Gayen S, et al
    Pulmonary Vasodilator Therapy Is Associated with Decreased Mortality in Patients with Chronic Lung Disease and Severe Pulmonary Hypertension.
    J Cardiovasc Dev Dis. 2024;11:89.
    PubMed    
    Abstract available
    
    

14. KULARATNE M, Gerges C, Jevnikar M, Humbert M, et al
    Updated Clinical Classification and Hemodynamic Definitions of Pulmonary Hypertension and Its Clinical Implications.
    J Cardiovasc Dev Dis. 2024;11:78.
    PubMed    
    Abstract available
    
    

15. USMANI SUR, Hasan SU, Ali SH, Ahmed SH, et al
    Perioperative sildenafil therapy in pulmonary hypertension associated with congenital cardiac disease: An updated meta-analysis.
    Asian J Surg. 2024 Mar 25:S1015-9584(24)00430.
    PubMed    
    Abstract available
    
    

16. YU H, Lee D, Chae Y, Choi M, et al
    Myxomatous mitral valve disease and associated pulmonary hypertension might increase serum angiopoietin-2 in dogs.
    Am J Vet Res. 2024 Mar 30:1-9. doi: 10.2460/ajvr.23.12.0289.
    PubMed    
    Abstract available
    
    

17. WANG C, Zhu Q, Tan D, Walline J, et al
    Acute High-Output Heart Failure with Pulmonary Hypertension and Severe Liver Injury Caused by Amlodipine Poisoning: A Case Report.
    Cardiovasc Toxicol. 2024 Mar 26. doi: 10.1007/s12012-024-09849.
    PubMed    
    Abstract available
    
    

18. ZHAO H, Song J, Li X, Xia Z, et al
    The role of immune cells and inflammation in pulmonary hypertension: mechanisms and implications.
    Front Immunol. 2024;15:1374506.
    PubMed    
    Abstract available
    
    

19. MAI H, Yang X, Xie Y, Zhou J, et al
    Identification of the shared hub gene signatures and molecular mechanisms between HIV-1 and pulmonary arterial hypertension.
    Sci Rep. 2024;14:7048.
    PubMed    
    Abstract available
    
    

20. WANG LY, Wang BJ, Gao XY
    [Research progress on auxiliary indexes and methods of diagnosis and treatment of patent ductus arteriosus in preterm].
    Zhonghua Er Ke Za Zhi. 2024;62:381-384.
    PubMed    
    
    
    

21. DENG X, Luo H, He J, Deng W, et al
    Omentin-1 ameliorates pulmonary arterial hypertension by inhibiting endoplasmic reticulum stress through AMPKalpha signaling.
    Clin Exp Hypertens. 2024;46:2332695.
    PubMed    
    Abstract available
    
    

22. KELLIHAN HB, Cutchin E, Sirochman A, Gasper D, et al
    Severe Pulmonary Hypertension and Pulmonary Thrombi in a Dog.
    CASE (Phila). 2023;8.
    PubMed    
    Abstract available
    
    

23. WAHADNEH OA, Alitter Q, Raju A, Alziadin N, et al
    Prevalence and Impact of Pulmonary Hypertension on Acute Decompensated Heart Failure with Preserved Ejection Fraction Hospitalizations: A Five-Year Retrospective Analysis.
    Curr Probl Cardiol. 2024 Mar 22:102537. doi: 10.1016/j.cpcardiol.2024.102537.
    PubMed    
    Abstract available
    
    

24. WU J, Ling Y
    A review regarding the article 'Impact of tricuspid regurgitation severity on mortality in pulmonary hypertension patients: A comprehensive analysis.
    Curr Probl Cardiol. 2024;49:102535.
    PubMed    
    Abstract available
    
    

25. KRZYZEWSKA A, Baranowska-Kuczko M, Galicka A, Kasacka I, et al
    Cannabidiol may prevent the development of congestive hepatopathy secondary to right ventricular hypertrophy associated with pulmonary hypertension in rats.
    Pharmacol Rep. 2024 Mar 22. doi: 10.1007/s43440-024-00579.
    PubMed    
    Abstract available
    
    

26. STUBBS HD, Cannon J, Knightbridge E, Durrington C, et al
    Sendaway capillary NT-proBNP in pulmonary hypertension.
    BMJ Open Respir Res. 2024;11:e002124.
    PubMed    
    Abstract available
    
    

27. WEATHERALD J, Nathan SD, El-Kersh K, Argula RG, et al
    Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study.
    BMJ Open Respir Res. 2024;11:e002116.
    PubMed    
    Abstract available
    
    

28. HNATJUK MS, Konovalenko SO, Kritsak MY, Gargula TI, et al
    Morphometric aspects of remodeling of the arterial bed of the testicles in post- resection portal and pulmonary hypertensions.
    Pol Merkur Lekarski. 2024;52:67-72.
    PubMed    
    Abstract available
    
    

29. VILLAS BOAS HJ, Paschoal IA, Pereira MC
    Impulse oscillometry in patients with pulmonary arterial hypertension: an exploratory study.
    Clinics (Sao Paulo). 2024;79:100313.
    PubMed    
    Abstract available
    
    

30. YAN X, Huang J, Zeng Y, Zhong X, et al
    CGRP attenuates pulmonary vascular remodeling by inhibiting the cGAS-STING-NFkappaB pathway in pulmonary arterial hypertension.
    Biochem Pharmacol. 2024;222:116093.
    PubMed    
    Abstract available
    
    

31. HOLT MF, Flo A, Ravnestad H, Bjorno V, et al
    Invasive haemodynamics at rest and exercise in cardiac amyloidosis.
    ESC Heart Fail. 2024;11:1263-1268.
    PubMed    
    Abstract available
    
    

32. SUBRAMANIAN P, Singhal M, Sharma A
    Unique segmental branching of right pulmonary artery in association with patent ductus arteriosus and anomalous carotid origin of left vertebral artery.
    Pediatr Pulmonol. 2024;59:1092-1094.
    PubMed    
    
    
    

33. YANG T, Li X, Luo Q, Zhao Q, et al
    Angiographic classification of total occlusion and its implication on balloon pulmonary angioplasty.
    ESC Heart Fail. 2024;11:795-804.
    PubMed    
    Abstract available
    
    

34. XUEYUAN L, Yanping X, Jiaoqiong G, Yuehui Y, et al
    Autonomic nervous modulation: early treatment for pulmonary artery hypertension.
    ESC Heart Fail. 2024;11:619-627.
    PubMed    
    Abstract available
    
    

35. RASHIDI F, Bilehjani E, Mousavi-Aghdas SA, Parvizi R, et al
    Massive primary pulmonary artery rhabomyosarcoma: A case report.
    Rom J Intern Med. 2024;62:67-74.
    PubMed    
    Abstract available
    
    

36. LI X, Song L, Lu Z, Tong S, et al
    Integrative analyses of whole-transcriptome sequencing reveals CeRNA regulatory network in pulmonary hypertension treated with FGF21.
    Int Immunopharmacol. 2024;132:111925.
    PubMed    
    Abstract available
    
    

37. ZHANG P, Da Silva Goncalves Bos D, Vang A, Feord J, et al
    Reduced exercise capacity occurs before intrinsic skeletal muscle dysfunction in experimental rat models of pulmonary hypertension.
    Pulm Circ. 2024;14:e12358.
    PubMed    
    Abstract available
    
    

38. KONG D, Liu J, Lu J, Zeng C, et al
    HMGB2 Release Promotes Pulmonary Hypertension and Predicts Severity and Mortality of Patients With Pulmonary Arterial Hypertension.
    Arterioscler Thromb Vasc Biol. 2024 Apr 4. doi: 10.1161/ATVBAHA.123.319916.
    PubMed    
    Abstract available
    
    

39. NASSAR GM, Jameson R, Sathiyaraj S, Bidikian N, et al
    Recovery from kidney failure associated with chronic thromboembolic pulmonary hypertension following pulmonary thomboendarterectomy.
    Clin Kidney J. 2024;17:sfae047.
    PubMed    
    Abstract available
    
    

40. XING Y, Hou Y, Fan T, Gao R, et al
    Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension.
    Acta Pharm Sin B. 2024;14:1726-1741.
    PubMed    
    Abstract available
    
    

41. OKI T, Nagatani Y, Ishida S, Hashimoto M, et al
    Right main pulmonary artery distensibility on dynamic ventilation CT and its association with respiratory function.
    Eur Radiol Exp. 2024;8:50.
    PubMed    
    Abstract available
    
    

42. GEGENAVA M, Gegenava T
    Association of pulmonary hypertension with outcomes in patients with Systemic sclerosis and other connective tissue disorders: review and meta-analysis.
    Sarcoidosis Vasc Diffuse Lung Dis. 2024;41:e2024023.
    PubMed    
    Abstract available
    
    

43. PRICE LC, Kouranos V, Baughman R, Bloom C, et al
    Use of pulmonary arterial hypertension therapies in patient swith sarcoidosis-associated pulmonary hypertension.
    Sarcoidosis Vasc Diffuse Lung Dis. 2024;41:e2024024.
    PubMed    
    
    
    

44. JAEGER P, Toskas I, Henes JK, Shcherbyna S, et al
    Impact of pulmonary hypertension on outcomes after TEER in patients suffering from mitral regurgitation.
    Clin Res Cardiol. 2024 Apr 2. doi: 10.1007/s00392-024-02442.
    PubMed    
    Abstract available
    
    

45. TANG M, Luo J, Liu Q, Song J, et al
    Coexistence of pulmonary arterial hypertension and straight back syndrome in a patient with a novel BMPR2 variant affecting cytoplasmic tail domain.
    Eur J Med Res. 2024;29:209.
    PubMed    
    Abstract available
    
    

46. HU X, Lv X, Zhang L, Li SS, et al
    Noncoding RNA Lipotherapeutics: A Promising Breakthrough in Pulmonary Hypertension Treatment.
    Curr Pharm Biotechnol. 2024 Mar 29. doi: 10.2174/0113892010302590240321073509.
    PubMed    
    Abstract available
    
    

47. VAN KALSBEEK D, Anani AR, El-Kersh K
    Pulmonary artery vasodilators for treatment of pulmonary hypertension complicating fibrosing mediastinitis.
    Respir Med Case Rep. 2024;49:102006.
    PubMed    
    Abstract available
    
    

48. KHEMCHANDANI M, Nasir K, Qureshi R, Dhrolia M, et al
    Frequency of Pulmonary Hypertension and Its Associated Risk Factors in End-Stage Renal Disease (ESRD) Patients on Maintenance Hemodialysis.
    Cureus. 2024;16:e55206.
    PubMed    
    Abstract available
    
    

49. KOZAILY E, Akdogan ER, Dorsey NS, Tedford RJ, et al
    Management of Pulmonary Hypertension in the Context of Heart Failure with Preserved Ejection Fraction.
    Curr Hypertens Rep. 2024 Apr 1. doi: 10.1007/s11906-024-01296.
    PubMed    
    Abstract available
    
    

50. WANG S, Li H, Liu Q, Ma H, et al
    Hydroxycitric Acid Tripotassium Hydrate Attenuates Monocrotaline and Hypoxia-Induced Pulmonary Hypertension in Rats.
    Int Heart J. 2024;65:318-328.
    PubMed    
    Abstract available
    
    

51. ZUO Y, Li B, Gao M, Xiong R, et al
    Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension.
    Respir Res. 2024;25:147.
    PubMed    
    Abstract available
    
    

52. CRITSER PJ, Buchmiller TL, Gauvreau K, Zalieckas JM, et al
    Exercise-induced Pulmonary Hypertension in Long-term Survivors of Congenital Diaphragmatic Hernia.
    J Pediatr. 2024 Mar 27:114034. doi: 10.1016/j.jpeds.2024.114034.
    PubMed    
    Abstract available
    
    

53. THE EDITORS OF THE LANCET RESP
    Retraction and republication-Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
    Lancet Respir Med. 2024;12:262-263.
    PubMed    
    
    
    

54. WANG J, Liu C, Huang SS, Wang HF, et al
    Functions and novel regulatory mechanisms of key glycolytic enzymes in pulmonary arterial hypertension.
    Eur J Pharmacol. 2024;970:176492.
    PubMed    
    Abstract available
    
    

55. CHEN Y, Liu J, Zhang Q, Chai L, et al
    Activation of CaMKII/HDAC4 by SDF1 contributes to pulmonary arterial hypertension via stabilization Runx2.
    Eur J Pharmacol. 2024;970:176483.
    PubMed    
    Abstract available
    
    

56. MARTINEZ-MENACA A, Mora-Cuesta VM, Iturbe-Fernandez D, Sainz-Ezquerra Belmonte B, et al
    Quality of Life and the Cardiopulmonary Exercise Test in Pulmonary Arterial Hypertension Patients.
    Arch Bronconeumol. 2024;60:253-255.
    PubMed    
    
    
    

57. DISTLER O, Ofner C, Huscher D, Jordan S, et al
    Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
    Rheumatology (Oxford). 2024;63:1139-1146.
    PubMed    
    Abstract available
    
    

58. TODOROKI Y, Satoh M, Kubo S, Kosaka S, et al
    Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease.
    Rheumatology (Oxford). 2024;63:1068-1075.
    PubMed    
    Abstract available
    
    

59. YOUSSEF M, Boutros Salama M, Rehman N, Hanna C, et al
    Pulmonary hypertension survival and hospitalisations in people living with HIV: a systematic review and meta-analysis.
    BMJ Open Respir Res. 2024;11:e002318.
    PubMed    
    Abstract available
    
    

60. ALBULUSHI A, Al-Asmi S, Al-Abri M, Al-Farhan H, et al
    The Road to Heart Transplant in a Patient With Cardiomyopathy, Shone Complex, and Severe Pulmonary Hypertension.
    JACC Case Rep. 2024;29:102323.
    PubMed    
    Abstract available
    
    

61. PAPAGEORGIOU ST, Damdoumis S, Goulis D, Tzikas S, et al
    The Effect of Pulmonary Hypertension on Mortality and Intensive Care Unit Admission in Patients With SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.
    Heart Lung Circ. 2024 Apr 9:S1443-9506(24)00076.
    PubMed    
    Abstract available
    
    

62. MORALES-CANO D, Barreira B, Callejo M, Olivencia MA, et al
    Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human.
    Vascul Pharmacol. 2024 Apr 8:107371. doi: 10.1016/j.vph.2024.107371.
    PubMed    
    Abstract available
    
    

63. SAKARIN S, Rungsipipat A, Roytrakul S, Jaresitthikunchai J, et al
    Proteomic analysis of the serum in dogs with pulmonary hypertension secondary to myxomatous mitral valve disease: the preliminary study.
    Front Vet Sci. 2024;11:1327453.
    PubMed    
    Abstract available
    
    

64. KISKADDON A, Dang T, Mauriello D
    Tadalafil in Neonates and Infants With Pulmonary Hypertension Secondary to Bronchopulmonary Dysplasia.
    J Pediatr Pharmacol Ther. 2024;29:140-143.
    PubMed    
    Abstract available
    
    

65. WANG T, Zhou D, Chen Y, Kuang S, et al
    Non-invasive estimation of pulmonary hypertension and clinical deterioration risk in pediatric congenital heart disease: Development and validation of predictive tools.
    Chin Med J (Engl). 2024 Apr 8. doi: 10.1097/CM9.0000000000003070.
    PubMed    
    
    
    

66. KOUDSTAAL T, van den Bosch T, Bergen I, Lila K, et al
    Predominance of M2 macrophages in organized thrombi in chronic thromboembolic pulmonary hypertension patients.
    Eur J Immunol. 2024 Apr 9:e2350670. doi: 10.1002/eji.202350670.
    PubMed    
    Abstract available
    
    

67. CHAUDHARI T, Schmidt Sotomayor N, Maheshwari R
    Diagnosis, management and long term cardiovascular outcomes of phenotypic profiles in pulmonary hypertension associated with congenital diaphragmatic hernia.
    Front Pediatr. 2024;12:1356157.
    PubMed    
    Abstract available
    
    

68. WEI X, Zou Y, Dong S, Chen Y, et al
    Recombinant hirudin attenuates pulmonary hypertension and thrombosis in acute pulmonary embolism rat model.
    PeerJ. 2024;12:e17039.
    PubMed    
    Abstract available
    
    

69. UGWENDUM D, Mbome Y, Arrey Agbor DB, Burkhanova U, et al
    Methylphenidate-Induced Non-ischemic Heart Failure With Reduced Ejection Fraction and Mild Pulmonary Hypertension.
    Cureus. 2024;16:e55604.
    PubMed    
    Abstract available
    
    

70. PASIANA AD, Idrus HH, Purnamasari I
    Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-kappaB Signaling Pathway to Attenuate Vascular Remodeling [LETTER].
    Drug Des Devel Ther. 2024;18:1023-1024.
    PubMed    
    
    
    

71. SHI TY, Wen XH, Meng J, Lu YW, et al
    Effect of IL-17 on pulmonary artery smooth muscle cells and connective tissue disease-associated pulmonary arterial hypertension.
    Immun Inflamm Dis. 2024;12:e1243.
    PubMed    
    Abstract available
    
    

72. CHAI Y, Gu X, Zhang H, Xu X, et al
    Phoenixin 20 ameliorates pulmonary arterial hypertension via inhibiting inflammation and oxidative stress.
    Aging (Albany NY). 2024;16:5027-5037.
    PubMed    
    Abstract available
    
    

73. LAU E, Kotlyar E, Makanji Y, Yu DY, et al
    Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study.
    J Med Econ. 2024;27:596-604.
    PubMed    
    Abstract available
    
    

74. STEGER M, Canuet M, Enache I, Goetsch T, et al
    Survival and response to pulmonary vasodilator therapies in patients with chronic obstructive pulmonary disease and pulmonary vascular phenotype.
    Respir Med. 2024;225:107585.
    PubMed    
    Abstract available
    
    

75. NJOKU F, Pugh N, Brambilla D, Kroner B, et al
    Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry.
    Am J Hematol. 2024;99:900-909.
    PubMed    
    Abstract available
    
    

76. CHALIA M, Seager E, Rao A, Hannam S, et al
    Transient abnormal myelopoiesis requiring advanced neonatal intensive care treatment.
    Acta Paediatr. 2024 Feb 8. doi: 10.1111/apa.17142.
    PubMed    
    Abstract available
    
    

77. MURPHY SP, Deferm S, Yucel E, Urbut SM, et al
    Right Ventricular - Pulmonary Arterial Coupling and All-Cause Mortality in Patients with Mitral Annular Calcification Related Mitral Valve Dysfunction.
    J Am Soc Echocardiogr. 2024 Jan 20:S0894-7317(24)00011.
    PubMed    
    
    
    

78. YE P, Deng Y, Gu Y, Liu P, et al
    GRK2-YAP signaling is implicated in pulmonary arterial hypertension development.
    Chin Med J (Engl). 2024;137:846-858.
    PubMed    
    Abstract available
    
    

79. MEGIED MAAE, Abouelhassan MA, Hadwa ESAES
    Prognostic and diagnostic utility of interleukin-6 in pediatric pulmonary arterial hypertension - a case-control study.
    Eur J Pediatr. 2024;183:1637-1643.
    PubMed    
    Abstract available
    
    

80. BESSA-GONCALVES M, Braganca B, Martins-Dias E, Vinhas A, et al
    Blockage of the adenosine A(2B) receptor prevents cardiac fibroblasts overgrowth in rats with pulmonary arterial hypertension.
    Purinergic Signal. 2024;20:163-179.
    PubMed    
    Abstract available
    
    

81. CELESKI M, Segreti A, Polito D, Valente D, et al
    Traditional and Advanced Echocardiographic Evaluation in Chronic Obstructive Pulmonary Disease: The Forgotten Relation.
    Am J Cardiol. 2024;217:102-118.
    PubMed    
    Abstract available
    
    

82. HATABAH D, De Marco T, McGlothlin DP, Malloy M, et al
    Low global arginine bioavailability: a common phenomenon in pulmonary hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2024;326:L514-L515.
    PubMed    
    
    
    

83. ALI M, Choudhary R, Singh K, Kumari S, et al
    Hypobaric hypoxia modulated structural characteristics of circulating cell-free DNA in high-altitude pulmonary edema.
    Am J Physiol Lung Cell Mol Physiol. 2024;326:L496-L507.
    PubMed    
    Abstract available
    
    

84. BJORKMAN KR, Miles KG, Bellew LE, Schneider KA, et al
    Patent Ductus Arteriosus and Lung MRI Phenotype in Moderate and Severe Bronchopulmonary Dysplasia-Pulmonary Hypertension.
    Am J Respir Crit Care Med. 2024 Apr 3. doi: 10.1164/rccm.202310-1733.
    PubMed    
    Abstract available
    
    

85. AL-NAAMANI N, Thenappan T
    Left Heart Disease Phenotype in Pulmonary Arterial Hypertension: Considerations for Therapy.
    Chest. 2024;165:766-768.
    PubMed    
    
    
    

86. KEARNEY K, Brown K, Celermajer DS, Collins N, et al
    Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy.
    Chest. 2024;165:967-977.
    PubMed    
    Abstract available
    
    

87. SHEN H, Gao Y, Ge D, Tan M, et al
    BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension.
    Circulation. 2024 Apr 1. doi: 10.1161/CIRCULATIONAHA.123.066430.
    PubMed    
    Abstract available
    
    

88. DATE N, Nakajima D, Ikeda M, Nishikawa S, et al
    Effect of epoprostenol-induced thrombocytopaenia on lung transplantation for pulmonary arterial hypertension.
    Eur J Cardiothorac Surg. 2024 Mar 27:ezae108. doi: 10.1093.
    PubMed    
    Abstract available
    
    

89. AGARWAL S, Fineman J, Cornfield DN, Alvira CM, et al
    VIEWING PULMONARY HYPERTENSION THROUGH A PEDIATRIC LENS.
    Eur Respir J. 2024 Apr 4:2301518. doi: 10.1183/13993003.01518-2023.
    PubMed    
    
    
    

90. GRYNBLAT J, Bogaard HJ, Eyries M, Meyrignac O, et al
    Pulmonary vascular phenotype identified in patients with GDF2 (BMP9) or BMP10 variants: an international multicentre study.
    Eur Respir J. 2024;63:2301634.
    PubMed    
    Abstract available
    
    

91. WOOLF B, Perry JA, Hong CC, Wilkins MR, et al
    Multi-biobank summary data Mendelian randomisation does not support a causal effect of IL-6 signalling on risk of pulmonary arterial hypertension.
    Eur Respir J. 2024;63:2302031.
    PubMed    
    Abstract available
    
    

92. KOSMIDIS D, Arvanitaki A, Farmakis IT, Liakos A, et al
    Pulmonary vasodilators and exercise in Fontan circulation: a systematic review and meta-analysis.
    Heart. 2024;110:552-559.
    PubMed    
    Abstract available
    
    

93. BEKHUIS Y, Verwerft J, Claessen G
    Exercise Echocardiography for mPAP/CO Slope Estimation: A New Standard for Routine Clinical Care?
    J Am Coll Cardiol. 2024;83:e141-e142.
    PubMed    
    
    
    

94. YENIDOGANAY R, Rancati V, Yerly P, Lu H, et al
    Atrial Flow Regulator: Should We Be Afraid of It?
    J Cardiothorac Vasc Anesth. 2024;38:1284-1286.
    PubMed    
    
    
    

95. CONZATTI A, Colombo R, Siqueira R, Campos-Carraro C, et al
    Sulforaphane improves redox homeostasis and right ventricular contractility in a model of pulmonary hypertension.
    J Cardiovasc Pharmacol. 2024 Mar 14. doi: 10.1097/FJC.0000000000001557.
    PubMed    
    Abstract available
    
    

96. KUMARI K, Vishwakarma VK, Kumar K, Mridha AR, et al
    Effect of benidipine alone and in combination with bosentan and sildenafil in amelioration of pulmonary arterial hypertension in experimental model in rats.
    J Cardiovasc Pharmacol. 2024 Jan 17. doi: 10.1097/FJC.0000000000001541.
    PubMed    
    Abstract available
    
    

97. BARBERA JA, Peinado VI, Blanco I
    UNTANGLING SEVERE PULMONARY HYPERTENSION IN COPD.
    J Heart Lung Transplant. 2024 Mar 22:S1053-2498(24)01538.
    PubMed    
    
    
    

98. GONG S, Li H, Wang L
    Pulmonary artery-pulmonary artery collaterals in chronic thromboembolic pulmonary hypertension.
    Thorax. 2024 Apr 10:thorax-2023-221219. doi: 10.1136/thorax-2023-221219.
    PubMed    
    
    
    

99. STACEL T, Kegler K, Medrala A, Sybila P, et al
    Lung Transplantation in Patients With Pulmonary Hypertension With Extracorporeal Membrane Oxygenation (ECMO) Support: 5-Year Experience.
    Transplant Proc. 2024 Apr 4:S0041-1345(24)00170.
    PubMed    
    Abstract available
    
    

100. YONEDA K, Seki T, Kawazoe Y, Ohe K, et al
     Immediate postnatal prediction of death or bronchopulmonary dysplasia among very preterm and very low birth weight infants based on gradient boosting decision trees algorithm: A nationwide database study in Japan.
     PLoS One. 2024;19:e0300817.
     PubMed    
     Abstract available
     
     

101. MATSUNAGA T, Kono A, Nishio M, Yoshii T, et al
     Development and web deployment of prediction model for pulmonary arterial pressure in chronic thromboembolic pulmonary hypertension using machine learning.
     PLoS One. 2024;19:e0300716.
     PubMed    
     Abstract available
     
     

102. ISHIBASHI T, Inagaki T, Okazawa M, Yamagishi A, et al
     IL-6/gp130 signaling in CD4(+) T cells drives the pathogenesis of pulmonary hypertension.
     Proc Natl Acad Sci U S A. 2024;121:e2315123121.
     PubMed    
     Abstract available